UPM Pharmaceuticals Manufacturing Facility

Formerly part of King College, the state-of-the-art facility has been primarily owned and operated by the UPM family legacy since its acquisition in the early nineties, and has since seen the successful scale-up of over 80 products to commercialization. Today, the facility continues to supply several commercial products, with the capacity to produce 700 million capsules, 4 billion tablets and 1,300,000 kilogram units of semi-solids for customers each year.

For 17 years, one of the most stable pharmaceutical companies in the US—King Pharmaceuticals—manufactured a portfolio of successful commercial products from the UPM facility. The site was also briefly owned and operated by Pfizer.

Facility Snapshot

The UPM site conducts large-scale commercial manufacturing and packaging of semi-solid creams and ointments as well as OSD drug product. Flexibly designed to provide full tech transfer and scale-up support, the facility has an extensive track record of optimizing processes to achieve commercial success. In addition to its production capacity, the site is also equipped to handle analytical, microbial and stability testing, with a full-service analytical laboratory to support the production of solids and semi-solids at all scales.

The site is DEA-licensed for Schedule II–V controlled substances and has over 15,800 square feet of DEA Approved vault space total.

Come Visit Us Today

At UPM, our partnerships thrive on transparency, as our doors are always open. We invite you to come to visit us in beautiful Bristol, Tennessee, tour our facility and sit down with our Executive Team to discuss how your project goals align with our capabilities and capacity.
SCHEDULE A TOUR & EXECUTIVE MEETING